ASX healthcare stocks look to partner up to fund drug development
ASX healthcare companies are increasingly looking to tap into licensing and partnering deals to fund...
ASX healthcare companies are increasingly looking to tap into licensing and partnering deals to fund...
As cancer rates around the world climb for a range of reasons, one of the...
One of the most advanced cancer therapies on the ASX, Prescient Therapeutics’ (ASX: PTX) PTX-100...
Small Caps speaks with Prescient Therapeutics (ASX: PTX) for a general company update focused on...
Special Report: Prescient Therapeutics has entered an important stage in development of its lead cancer...
Special Report: Clinical-stage oncology company Prescient Therapeutics has reached a key milestone in the Phase 2a...
rescient Therapeutics (ASX: PTX) is advancing PTX100, a first-in-class oncology asset being evaluated in cutaneous...
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b...
Prescient Therapeutics (ASX:PTX) is at the forefront of this approach with PTX-100, a small molecule which...
Prescient Therapeutics Ltd (ASX:PTX) is seeking to raise up to $7 million through a Share Purchase...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.